Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS-1: Hemodynamic effects of a single dose of sildenafil in PAH patients on bosentan
2005-005066-37Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sildenafil in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Pulmonary vascular resistance percent change from baseline. Started Feb 2006; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-005066-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005066-37.